GENERA, Centre for Reproductive Medicine, Clinica Valle Giulia, Rome, Italy; GENETYX, Molecular Genetics Laboratory, Gruppo Salus, Vicenza, Italy.
GENERA, Centre for Reproductive Medicine, Clinica Valle Giulia, Rome, Italy; GENETYX, Molecular Genetics Laboratory, Gruppo Salus, Vicenza, Italy.
Fertil Steril. 2017 Jan;107(1):12-18. doi: 10.1016/j.fertnstert.2016.11.002.
Chromosome deletions and duplications-copy number variations (CNVs)-are a major contribution to the genome variability and can be either pathogenic or not. A particular class, the microdeletions and microduplications, which alter <5 Mb, have been extensively associated with developmental delay and intellectual disability. Although their prevalence in pregnancies and newborn is relatively low, their estimates in preimplantation embryos are poorly defined. The introduction of novel technologies for preimplantation genetic diagnosis of aneuploidies (PGD-A) caused new possibilities and challenges associated with diagnosis of subchromosomal CNVs. Both technical aspects of performing genomewide microarray or next generation sequencing analysis on single cells and interpretation issues are subject of debate. The latter include the reliability of detection of CNVs from embryonic biopsies, their clinical classification based on reproductive outcomes, as well as how before and after test counseling should be organized. It is also important to consider that the current resolution of these technologies from single cells is usually >10 Mb, thus ruling out the possibility to diagnose the most important recurrent microdeletion and microduplication syndromes. Furthermore, at present we face with a lack of well-designed studies addressing the actual resolution and accuracy of CNVs detection in PGD-A and no reference databases is available to evaluate their pathogenicity. Accordingly, it seems reasonable at the moment to avoid the reporting of subchromosomal CNVs in PGD-A. However, although these issues require proper handling, they should not lead us away from providing an improved preimplantation genetic diagnosis.
染色体缺失和重复(拷贝数变异,CNVs)是基因组变异的主要原因,它们可能具有致病性,也可能没有致病性。一类特殊的微缺失和微重复,其改变 <5 Mb,与发育迟缓及智力障碍广泛相关。尽管它们在妊娠和新生儿中的发生率相对较低,但在胚胎植入前的发生率定义并不明确。植入前遗传诊断非整倍体(PGD-A)新技术的出现带来了与亚染色体 CNVs 诊断相关的新的可能性和挑战。单细胞全基因组微阵列或下一代测序分析的技术方面和解释问题都存在争议。后者包括从胚胎活检中检测 CNVs 的可靠性、基于生殖结局的临床分类,以及如何组织检测前和检测后的咨询。同样重要的是要考虑到,这些单细胞技术的当前分辨率通常 >10 Mb,从而排除了诊断最重要的常染色体微缺失和微重复综合征的可能性。此外,目前我们面临的问题是缺乏针对 PGD-A 中 CNVs 检测的实际分辨率和准确性的精心设计的研究,也没有参考数据库来评估其致病性。因此,目前似乎合理的做法是避免在 PGD-A 中报告亚染色体 CNVs。然而,尽管这些问题需要妥善处理,但不应使我们偏离提供更好的植入前遗传诊断。